Grant: Master's Award: Canada Graduate Scholarships
University of Alberta
$27,000.00
Determining the role of fatty acid binding protein 4 in lymphedema
EF 2024-25
Résumé
Lymphedema is a chronic, incapacitating condition where swelling occurs due to lymphatic fluid buildup in tissues, progressively worsening if untreated. As the affected limb deteriorates, symptoms like fat buildup, scar tissue, pain, and infection risk lead to a diminished quality of life. Cancer treatments that damage the lymphatic system increase the likelihood of developing lymphedema, yet it remains unclear why only some people develop it, and the cellular mechanisms behind the risk factors are poorly understood. Individuals with obesity are at greater risk of developing lymphedema and have higher levels of saturated fatty acids in their blood. Individuals with lymphedema have an imbalance in circulating saturated and polyunsaturated fatty acids. Certain fatty acids can trigger lymphatic cell death, and high levels of saturated fats may play a role in lymphedema development. Fatty acid binding protein 4 (FABP4) helps transport saturated fatty acids into cells, and blocking this protein can reduce lymphatic cell death caused by these fatty acids. My research focuses on the role of FABP4 in lymphedema. I will use genetically modified mice lacking FABP4, surgically inducing lymphedema in their tails while feeding them standard or high-saturated fat diets. I will assess the effects of removing FABP4 by comparing tail swelling, cell death, and inflammation between these mice and those that have the protein. Additionally, I will modify human lymphatic cells to overproduce, lack, or carry an altered form of this protein to observe its effects on cell function and response to fatty acids. By uncovering the role of this protein in lymphedema, this research will enhance our understanding of lymphedema risk mechanisms and aid in identifying much-needed novel therapies.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
529796
Name
Korodimas Jacob V
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Determining the role of fatty acid binding protein 4 in lymphedema
Programtype2
Studentship Programs
Orgnameinp2
University of Alberta
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer Care; Cellular Stress; Fatty Acid Binding Protein 4 (Fabp4); Lipotoxicity; Lymphatic Biology; Lymphedema; Murine Fabp4 Knockout; Obesity; Oncology; Saturated Fatty Acids
Abstract
Lymphedema is a chronic, incapacitating condition where swelling occurs due to lymphatic fluid buildup in tissues, progressively worsening if untreated. As the affected limb deteriorates, symptoms like fat buildup, scar tissue, pain, and infection risk lead to a diminished quality of life. Cancer treatments that damage the lymphatic system increase the likelihood of developing lymphedema, yet it remains unclear why only some people develop it, and the cellular mechanisms behind the risk factors are poorly understood. Individuals with obesity are at greater risk of developing lymphedema and have higher levels of saturated fatty acids in their blood. Individuals with lymphedema have an imbalance in circulating saturated and polyunsaturated fatty acids. Certain fatty acids can trigger lymphatic cell death, and high levels of saturated fats may play a role in lymphedema development. Fatty acid binding protein 4 (FABP4) helps transport saturated fatty acids into cells, and blocking this protein can reduce lymphatic cell death caused by these fatty acids. My research focuses on the role of FABP4 in lymphedema. I will use genetically modified mice lacking FABP4, surgically inducing lymphedema in their tails while feeding them standard or high-saturated fat diets. I will assess the effects of removing FABP4 by comparing tail swelling, cell death, and inflammation between these mice and those that have the protein. Additionally, I will modify human lymphatic cells to overproduce, lack, or carry an altered form of this protein to observe its effects on cell function and response to fatty acids. By uncovering the role of this protein in lymphedema, this research will enhance our understanding of lymphedema risk mechanisms and aid in identifying much-needed novel therapies.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Korodimas, Jacob V
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~